Endpoints News
A fresh batch of compounded GLP-1 warnings Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
17 June, 2026
Manufacturing Day 2026
Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.
top stories
1. After Makary's exit, FDA is giving CRL recipients another chance
2. FDA warns telehealth companies over compounded GLP-1s
3. UK waitlist for Novo's Wegovy pill triples in week after approval, major online pharmacy says
4. $25M ransom, no deal: Hackers claim Novo's drug recipes and AI models are for sale
5. In another reversal, FDA gives uniQure accelerated approval path for Huntington's gene therapy
6. Jazz turns to AbCellera for T cell engagers against GI cancers in up to $4.1B deal
more stories
 
Lydia Ramsey Pflanzer
.

If three's a trend, the potential reversal of four recent CRLs certainly signals a new approach from the FDA around rare disease drugs. Zach Brennan has the story about what that could mean for other drugmakers looking to change their fate.

.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
1
by Zachary Brennan

Did you re­ceive a com­plete re­sponse let­ter in the past year? Now may be the time for a re­sub­mis­sion.

In the wake of FDA Com­mis­sion­er...

Read the full story
2
by Shelby Livingston

The FDA has is­sued a new batch of warn­ing let­ters to 25 tele­health com­pa­nies, ac­cus­ing them of mak­ing false and mis­lead­ing claims in their mar­ket­ing...

Read the full story
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
3
by Ayisha Sharma

The wait­ing list at a UK on­line phar­ma­cy for No­vo Nordisk’s We­govy pill now stands at 30,000 peo­ple a week af­ter ap­proval, in a sign...

Read the full story
4
by Elizabeth Cairns

No­vo Nordisk got robbed and is in the un­en­vi­able po­si­tion of be­ing ex­tort­ed by the thieves. At stake, ac­cord­ing to a group that has claimed...

Read the full story
5
by Max Gelman

Reg­u­la­to­ry flex­i­bil­i­ty ap­pears to be back on the FDA’s menu fol­low­ing the de­par­tures of Mar­ty Makary and Vinay Prasad.

At the cen­ter of the...

Read the full story
AbCellera CEO Carl Hansen (L) and Jazz Pharmaceuticals' Joshua Allen
6
by Kyle LaHucik

For much of its first decade, Cana­di­an an­ti­body de­vel­op­er Ab­Cellera signed part­ner­ship af­ter part­ner­ship, se­cur­ing 40 bio­phar­ma al­liances that led to more than a dozen...

Read the full story
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com